Global Contraceptive Drugs and Devices Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Contraceptive Method;
Sterilization, Pills, Implants, Injectable, Intrauterine Device (IUD), Male Condoms, Vaginal Barrier Methods, and Natural Product.By Mode of Delivery;
Oral Contraceptives, Topical Contraceptives, and Contraceptive Injectables.By Device;
Condoms, Diaphragms, Cervical Caps, Sponges, Vaginal Rings, Intrauterine Device (IUD), and Implants.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Contraceptive Drugs and Devices Market (USD Million), 2021 - 2031
In the year 2024, the Global Contraceptive Drugs and Devices Market was valued at USD 6,834.16 million. The size of this market is expected to increase to USD 9,616.36 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.0%.
The global contraceptive drugs and devices market represents a vital segment within the broader healthcare industry, catering to the diverse contraceptive needs of individuals worldwide. With an ever-growing population and increasing awareness about family planning and reproductive health, the demand for effective contraceptive solutions continues to rise. This market encompasses a wide array of products ranging from oral contraceptives and intrauterine devices (IUDs) to contraceptive patches and implants, offering various options to suit individual preferences and needs.
Advancements in contraceptive technology and innovations in drug delivery systems have significantly enhanced the efficacy and convenience of contraceptive methods, thereby driving market growth. Moreover, the expansion of healthcare infrastructure, coupled with government initiatives aimed at promoting family planning and reproductive health, further propels the adoption of contraceptive drugs and devices globally. Additionally, the growing focus on gender equality and women's empowerment has spurred the demand for contraceptives, empowering individuals to make informed choices about their reproductive health.
Despite the considerable strides made in contraceptive technology and accessibility, challenges such as socio-cultural barriers, inadequate healthcare infrastructure in certain regions, and concerns regarding side effects persist, hindering market expansion to some extent. Nevertheless, ongoing research and development efforts aimed at introducing novel contraceptive options with improved safety profiles and user-friendliness are expected to drive market growth in the coming years. As societies continue to prioritize reproductive health and family planning initiatives, the global contraceptive drugs and devices market is poised for steady expansion, catering to the evolving needs of individuals and communities worldwide.
Global Contraceptive Drugs and Devices Market Recent Developments
-
In Febraury 2023, Agile Therapeutics, a pharmaceutical company focused on women’s healthcare, announced a clinical update on Twirla and the status of its pipeline evaluation. Twirla is a transdermal contraceptive patch that delivers combined hormones and is applied once a week. The U.S. Food and Drug Administration (FDA) has agreed to consider its approval using electronic health records (EHR) and insurance claims data from a large healthcare system database.
-
In June 2024, Bayer AG, a leading global pharmaceutical company, introduced a new hormonal intrauterine device (IUD) that offers enhanced efficacy and a longer duration of action. This product provides women with a reliable and long-lasting contraceptive solution, delivering an extended period of protection compared to other options. Its improved design ensures better performance, meeting the growing demand for effective, low-maintenance contraceptive methods.
Segment Analysis
The global contraceptive drugs and devices market exhibits a diverse landscape segmented by contraceptive method, mode of delivery, and device type, offering a wide range of options to address varying needs and preferences. Sterilization procedures, including tubal ligation and vasectomy, stand as enduring methods for long-term contraception, offering permanent solutions for individuals seeking to prevent pregnancy. Conversely, oral contraceptives, injectables, and implantable devices provide reversible alternatives, allowing users to regulate fertility without committing to permanent interventions. Additionally, the market encompasses barrier methods such as male condoms, vaginal barriers, and natural products, offering non-invasive options for contraception.
Mode of delivery plays a crucial role in the contraceptive landscape, further diversifying the market offerings. Oral contraceptives, in the form of pills, represent one of the most widely utilized methods, offering convenience and ease of administration. Topical contraceptives, including patches and gels, provide alternative delivery mechanisms, allowing users to apply contraceptives directly to the skin for absorption. Contraceptive injectables present another mode of delivery, offering a longer duration of action compared to oral methods, appealing to individuals seeking less frequent dosing regimens.
Device-based contraceptives constitute a significant segment within the market, providing a variety of options tailored to individual preferences and needs. Male and female condoms remain ubiquitous choices for barrier contraception, offering protection against sexually transmitted infections (STIs) in addition to preventing pregnancy. Other devices such as diaphragms, cervical caps, and sponges provide additional barrier options, while vaginal rings, intrauterine devices (IUDs), and implants offer longer-term contraceptive solutions with varying degrees of effectiveness and ease of use. The diverse array of contraceptive drugs and devices available underscores the importance of catering to individual preferences and needs in promoting reproductive health and family planning initiatives worldwide.
Global Contraceptive Drugs and Devices Segment Analysis
In this report, the Global Contraceptive Drugs and Devices Market has been segmented by Contraceptive Method, Mode of Delivery, Device, and Geography.
Global Contraceptive Drugs and Devices Market, Segmentation by Contraceptive Method
The Global Contraceptive Drugs and Devices Market has been segmented by Contraceptive Method into Sterilization, Pills, Implants, Injectable, Intrauterine Device (IUD), Male Condoms, Vaginal Barrier Methods, and Natural Product.
The market also encompasses intrauterine devices (IUDs), which have gained popularity due to their high effectiveness rates and long-term contraceptive benefits. Male condoms continue to be widely utilized for their dual function in preventing both pregnancy and sexually transmitted infections (STIs). Additionally, various vaginal barrier methods, including diaphragms, cervical caps, and sponges, provide additional options for individuals seeking non-hormonal contraception. Natural products, such as fertility awareness methods and withdrawal, offer alternatives for those who prefer non-invasive and hormone-free approaches to family planning.
As the global population continues to grow and awareness about reproductive health increases, the demand for diverse contraceptive methods is expected to rise. This segmentation underscores the importance of offering a wide range of options to cater to the unique needs and preferences of individuals worldwide. Moreover, advancements in contraceptive technology and innovations in delivery systems are likely to further enhance the effectiveness, safety, and convenience of available methods, driving market growth and facilitating greater access to reliable contraception for all.
Global Contraceptive Drugs and Devices Market, Segmentation by Mode of Delivery
The Global Contraceptive Drugs and Devices Market has been segmented by Mode of Delivery into Oral Contraceptives, Topical Contraceptives, and Contraceptive Injectables.
Oral contraceptives, the market includes topical contraceptives, which encompass a range of products such as patches and gels that are applied directly to the skin for absorption. These topical options provide an alternative mode of delivery, offering users flexibility and convenience in administering contraception. Patches, for example, are typically applied to the skin once a week and release hormones to prevent ovulation, while contraceptive gels offer a non-invasive and discreet option for those seeking hormone-based contraception. The availability of topical contraceptives adds to the diversity of choices available to individuals, enabling them to select a method that aligns with their lifestyle and preferences.
Contraceptive injectables represent another significant mode of delivery within the market, offering longer-acting contraception compared to oral and topical methods. Injectable contraceptives, typically administered by healthcare professionals, provide users with a convenient and highly effective option for preventing pregnancy. These injections, which contain synthetic hormones such as progestin, offer protection against pregnancy for extended periods, ranging from one to three months depending on the formulation. As such, contraceptive injectables appeal to individuals seeking contraception with less frequent administration requirements, contributing to the overall diversity and accessibility of contraceptive options in the global market.
Global Contraceptive Drugs and Devices Market, Segmentation by Device
The Global Contraceptive Drugs and Devices Market has been segmented by Device into Condoms, Diaphragms, Cervical Caps, Sponges, Vaginal Rings, Intrauterine Device (IUD), and Implants.
The segmentation of the Global Contraceptive Drugs and Devices Market by device reflects the wide array of options available to individuals seeking contraception, catering to diverse preferences and needs. Condoms, both male and female, stand as ubiquitous choices offering dual protection against pregnancy and sexually transmitted infections (STIs). Their ease of accessibility and non-invasive nature make condoms a popular contraceptive method globally. Diaphragms and cervical caps are barrier methods that provide physical barriers to prevent sperm from reaching the cervix, offering effective and hormone-free contraception options for individuals seeking non-hormonal alternatives.
Sponges represent another device-based contraceptive option, typically containing spermicide and inserted into the vagina before intercourse to block sperm and release spermicidal agents. Vaginal rings offer a longer-acting hormonal contraceptive option, releasing hormones to prevent ovulation and alter cervical mucus consistency. Intrauterine devices (IUDs) have gained popularity for their high efficacy rates and long-term contraceptive benefits. Available in hormonal and non-hormonal varieties, IUDs are inserted into the uterus and provide reliable contraception for several years, offering convenience and effectiveness to users.
Implants represent a highly effective long-acting contraceptive method, consisting of small, flexible rods inserted under the skin of the upper arm. These implants release hormones to prevent ovulation and alter cervical mucus, offering contraception for up to several years. The segmentation of the market by device underscores the importance of offering a diverse range of options to cater to individual preferences and needs, ensuring greater accessibility and efficacy in meeting global contraceptive demands.
Global Contraceptive Drugs and Devices Market, Segmentation by Geography
In this report, the Global Contraceptive Drugs and Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Contraceptive Drugs and Devices Market Share (%), by Geographical Region, 2024
North America, comprising the United States and Canada, stands as a mature market characterized by high awareness levels, advanced healthcare infrastructure, and widespread access to contraceptive options. Innovations in contraceptive technology and increasing emphasis on reproductive health drive market growth in this region, with a focus on offering diverse and convenient contraceptive solutions to meet the evolving needs of individuals.
Europe represents another significant market segment, encompassing countries with varying healthcare systems and cultural attitudes towards contraception. Countries such as Germany, France, and the United Kingdom exhibit high contraceptive usage rates, supported by comprehensive healthcare coverage and government initiatives promoting family planning and reproductive health. Moreover, advancements in contraceptive research and development contribute to the availability of innovative products catering to diverse consumer preferences. However, challenges such as socio-cultural factors and disparities in access to healthcare services may influence market dynamics within the region.
The Asia Pacific region presents immense growth potential in the contraceptive drugs and devices market, driven by factors such as rapid population growth, increasing awareness about family planning, and rising healthcare expenditure. Countries like China and India, with large populations and evolving healthcare infrastructures, offer significant opportunities for market expansion. Government initiatives aimed at promoting contraceptive usage and improving access to reproductive healthcare services further bolster market growth in this region. Additionally, cultural norms and preferences influence the adoption of specific contraceptive methods, prompting manufacturers to tailor their offerings to meet the diverse needs of consumers across different Asian markets.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Contraceptive Drugs and Devices Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing awareness about reproductive health
- Growing demand for family planning solutions
-
Expansion of healthcare infrastructure - The expansion of healthcare infrastructure plays a pivotal role in shaping the dynamics of the Global Contraceptive Drugs and Devices Market. As healthcare infrastructure improves in various regions worldwide, access to contraceptive services and products becomes more widespread. Increased availability of healthcare facilities, including clinics and hospitals, enhances individuals' access to reproductive healthcare services, including consultations, screenings, and contraceptive provision. This expansion enables more people to make informed choices about family planning and contraception, thereby driving the demand for contraceptive drugs and devices.
The expansion of healthcare infrastructure facilitates the dissemination of accurate information and education regarding contraceptive methods and their usage. Healthcare providers can offer counseling and guidance to individuals, helping them select the most suitable contraceptive options based on their preferences, medical history, and lifestyle. Accessible healthcare facilities also enable timely interventions and follow-ups, ensuring effective contraceptive management and addressing any concerns or side effects that may arise. Consequently, the confidence and trust in contraceptive methods increase, leading to greater adoption and utilization rates.
The expansion of healthcare infrastructure fosters collaborations and partnerships between governmental organizations, non-profit entities, and private sectors to promote reproductive health initiatives. Through joint efforts, stakeholders can implement comprehensive programs aimed at increasing awareness, improving access, and reducing barriers to contraceptive usage. These initiatives may include subsidized contraceptive distribution programs, community-based outreach campaigns, and training healthcare providers in contraceptive counseling and provision. Overall, the expansion of healthcare infrastructure not only improves access to contraceptive drugs and devices but also contributes to broader public health goals related to reproductive health and family planning.
Restraints
- Socio-cultural barriers
- Concerns regarding side effects
-
Inadequate healthcare infrastructure - Inadequate healthcare infrastructure poses significant challenges to the Global Contraceptive Drugs and Devices Market, hindering access to essential reproductive healthcare services and products in many regions worldwide. Limited healthcare facilities, particularly in rural and remote areas, result in reduced availability of contraceptive counseling, screenings, and provision. As a consequence, individuals in these underserved areas may face barriers in accessing contraceptives, leading to lower contraceptive prevalence rates and higher incidences of unintended pregnancies. Inadequate infrastructure also limits the capacity of healthcare providers to offer comprehensive family planning services, exacerbating disparities in contraceptive access and utilization.
The lack of healthcare infrastructure contributes to gaps in knowledge and awareness regarding contraceptive methods and their usage. Without access to healthcare facilities or trained healthcare providers, individuals may rely on inaccurate information or traditional methods of contraception, potentially resulting in ineffective or unsafe practices. This lack of education and guidance regarding contraceptive options can lead to misconceptions, fears, and misconceptions about contraceptive methods, further impeding their adoption and utilization. Inadequate infrastructure also limits opportunities for individuals to receive timely interventions and support for managing contraceptive side effects or complications, exacerbating concerns and hesitancies surrounding contraceptive use.
The absence of adequate healthcare infrastructure undermines efforts to implement comprehensive reproductive health programs and initiatives aimed at promoting family planning and contraceptive access. Without sufficient healthcare facilities and resources, governments and non-profit organizations struggle to reach underserved populations with essential reproductive healthcare services and products. This perpetuates inequalities in contraceptive access and utilization, particularly among marginalized communities and vulnerable populations. Addressing the challenges posed by inadequate healthcare infrastructure requires concerted efforts to strengthen healthcare systems, improve accessibility, and invest in education and awareness programs to empower individuals to make informed choices about their reproductive health.
Opportunities
- Untapped emerging markets
- Development of novel contraceptive methods
-
Focus on gender equality - A heightened focus on gender equality has emerged as a driving force shaping the dynamics of the Global Contraceptive Drugs and Devices Market. Efforts to promote gender equality recognize the importance of empowering individuals, particularly women, to make autonomous decisions about their reproductive health and family planning. Access to a diverse range of contraceptive options enables individuals to exercise greater control over their fertility and reproductive choices, thereby promoting gender equity by reducing the burden of unintended pregnancies and empowering women to pursue educational and career opportunities.
Initiatives aimed at promoting gender equality often prioritize increasing access to contraceptive services and products, particularly in regions where disparities in contraceptive access and utilization persist. By expanding access to contraceptives, governments, non-profit organizations, and healthcare providers can address systemic barriers that hinder women's ability to make informed choices about their reproductive health. This includes providing comprehensive education and counseling on contraceptive methods, ensuring affordability and availability of contraceptives, and dismantling societal norms and cultural barriers that limit women's autonomy and decision-making authority.
A focus on gender equality within the contraceptive market drives innovation and development of products tailored to women's needs and preferences. This includes the introduction of novel contraceptive methods with improved safety profiles, reduced side effects, and increased user-friendliness. Additionally, initiatives to promote gender equality foster collaborations between stakeholders to address broader social determinants of health that impact women's access to contraceptives, such as education, economic empowerment, and social norms. By prioritizing gender equality within the contraceptive market, stakeholders can contribute to broader efforts to advance women's rights, improve health outcomes, and promote sustainable development globally.
Competitive Landscape Analysis
Key players in Global Contraceptive Drugs and Devices Market include;
- Bayer Healthcare
- Pfizer
- Merck & Co.
- Teva Pharmaceuticals, Ltd.
- Agile Therapeutics
- Actavis Plc
- Ani Pharmaceuticals, Inc.
- Church & Dwight, Co. Inc.
- Fuji Latex Co., Ltd
- Johnson & Johnson
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Contraceptive Method
- Market Snapshot, By Mode of Delivery
- Market Snapshot, By Device
- Market Snapshot, By Region
- Global Contraceptive Drugs and Devices Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing awareness about reproductive health
- Growing demand for family planning solutions
- Expansion of healthcare infrastructure
- Restraints
- Socio-cultural barriers
- Concerns regarding side effects
- Inadequate healthcare infrastructure
- Opportunities
- Untapped emerging markets
- Development of novel contraceptive methods
- Focus on gender equality
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Contraceptive Drugs and Devices Market, By Contraceptive Method, 2021 - 2031 (USD Million)
- Sterilization
- Pills
- Implants
- Injectable
- Intrauterine Device (IUD)
- Male Condoms
- Vaginal Barrier Methods
- Natural Product
- Global Contraceptive Drugs and Devices Market, By Mode of Delivery, 2021 - 2031 (USD Million)
- Oral Contraceptives
- Topical Contraceptives
- Contraceptive Injectables
- Global Contraceptive Drugs and Devices Market, By Device, 2021 - 2031 (USD Million)
- Condoms
- Diaphragms
- Cervical Caps
- Sponges
- Vaginal Rings
- Intrauterine Device (IUD)
- Implants
- Global Contraceptive Drugs and Devices Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Contraceptive Drugs and Devices Market, By Contraceptive Method, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Bayer Healthcare
- Pfizer
- Merck & Co.
- Teva Pharmaceuticals, Ltd.
- Agile Therapeutics
- Actavis Plc
- Ani Pharmaceuticals, Inc.
- Church & Dwight, Co. Inc.
- Fuji Latex Co., Ltd
- Johnson & Johnson
- Company Profiles
- Analyst Views
- Future Outlook of the Market